Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer
Zhou Y, Zhang X, Gao Y, Peng Y, Liu P, Chen Y, Guo C, Deng G, Ouyang Y, Zhang Y, Han Y, Cai C, Shen H, Gao L, Zeng S. Neuromedin U receptor 1 deletion leads to impaired immunotherapy response and high malignancy in colorectal cancer. IScience 2024, 27: 110318. PMID: 39055918, PMCID: PMC11269305, DOI: 10.1016/j.isci.2024.110318.Peer-Reviewed Original ResearchNeuromedin U receptor 1Colorectal cancerCytotoxic T-lymphocyte-associated protein 4CD8<sup>+</sup> T cell infiltrationCD8<sup>+</sup> T cellsLymphocyte activation gene-3Improve immunotherapy outcomesT cell infiltrationComprehensive multi-omics analysisPersonalized immunotherapy strategiesPatient-derived tissuesColorectal cancer cell linesColorectal cancer treatmentImmunotherapy outcomesImmune checkpointsImmunotherapy efficacyImmunotherapy strategiesImmunotherapy responsePrognostic significanceImmune infiltrationT cellsMulti-omics analysisCell infiltrationGenetic alterationsHigh malignancy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply